AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca
Bull Case

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

• AstraZeneca PLC demonstrated strong financial momentum in its second-quarter 2026 results, with core earnings per share rising 18% on a constant exchange rate basis to $2.63, comfortably exceeding the $2.48 expected by analysts, while total revenue grew by 6% and core operating profit increased by 11%.
• The company is actively expanding its oncology portfolio, which is a key driver of its growth, by securing global rights to Zegfrovy from Dizal Pharmaceutical for an upfront payment of $600 million, with the potential total deal value reaching $1.5 billion if development and sales milestones are met.
• Wall Street maintains a positive outlook on the stock, with a consensus rating of Moderate Buy and a consensus price target of $15,216.70 as of August 15, 2026, which suggests significant upside potential from the current stock price of $11,962.00.
• AstraZeneca PLC is pursuing a long-term funding strategy to support its operations, evidenced by the pricing of a €2.55 billion Eurobond in August 2026, which provides the capital necessary to sustain its ambitious goal of reaching $80 billion in annual revenue by 2030.
• The company continues to deliver positive clinical data in its core therapy areas, reporting favorable results for its lung cancer drugs Tagrisso and Enhertu in August 2026, which reinforces its position as a leader in the oncology sector.